Shanghai Hile Bio-technology Co., Ltd. - MacroPolo Shanghai Hile Bio-technology Co., Ltd. - MacroPolo
Healthcare

As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.

On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work

outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.

The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.

Shanghai Hile Bio-technology Co., Ltd.

Shanghai Hile Bio-technology Co., Ltd.

Company Overview

COMPANY DESCRIPTION

Hile Bio-Technology is primarily an animal vaccines maker with a strong focus on hog vaccines. In early 2017, the company established a joint venture in China with Argentina’s Biogénse Bagó S.A. and is building a sales network to tap global markets.

CHAIRPERSON

Zhang Haiming

HEADQUARTERS

Shanghai

PHONE

(021) 6089.0892

EMAIL

ir@hile-bio.com